Why the study?
Does switching to dabigatran resolve left atrial appendage thrombus in a patient with persistent atrial fibrillation and MTHFR mutation who failed rivaroxaban therapy?
Does switching to dabigatran resolve left atrial appendage thrombus in a patient with persistent atrial fibrillation and MTHFR mutation who failed rivaroxaban therapy?
Dabigatran may be an effective therapeutic option for resolving left atrial appendage thrombus in patients with atrial fibrillation and MTHFR mutation who fail rivaroxaban therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Szegedi et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: